ADT-OH

• Description:

  ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases[1][5].

• Product Name Alternative:

  5- (4-Hydroxyphenyl) -3H-1,2-dithiole-3-thione; ACS 1

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; FAK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/adt-oh.html

• Concentration:

  10mM

• Purity:

  98.55

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  S=C1SSC(C2=CC=C(O)C=C2)=C1

• Molecular Formula:

  C9H6OS3

• Molecular Weight:

  226.35

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Cai F, et al. ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. Cell Death Dis. 2020;11 (1) :33.|[2]Yu S, et al. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission. Cell Death Dis. 2024 Jun 28;15 (6) :463. |[3]Xu H, et al. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. Cancer Med. 2023 Aug;12 (16) :17193-17211.|[4]Wei SW, et al. Role of the hydrogen sulfide-releasing donor ADT-OH in the regulation of mammal neural precursor cells. J Cell Physiol. 2022 Jul;237 (7) :2877-2887.|[5]Li CY, et al. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways. Eur J Pharmacol. 2019 Dec 1;864:172719.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [18274-81-2]